[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"excessive-sleepiness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:excessive-sleepiness":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100559763","phase-3-studying-solriamfetol-modulation-of-taar-1-dopamine-and-norepinephrine-in-shift-work-disorder-sustain-100559763",false,"NCT06568367","Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)","A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder","Inclusion Criteria:\n\n* Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD)\n* Provides written informed consent to participate in the study before the conduct of any study procedures.\n* Male or female, aged 18 to 65 inclusive.\n\nExclusion Criteria:\n\n* Prior exposure to solriamfetol\u002FSunosi, through either a clinical study or prescription.\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},520,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).",[27,28],"Excessive Sleepiness","Shift-work Disorder",[27,30,31,32,33,34,35,36,37],"Solriamfetol","Sunosi","SWD","Dopamine norepinephrine reuptake inhibitor","Non-stimulant therapy","Insomnia","Circadian Rhythm Sleep Disorder","Trace amine-associated receptor 1 (TAAR1) agonist","RECRUITING","2025-11-20",{"date":41,"type":42},"2025-11-25","ACTUAL",{"date":44,"type":42},"2024-08-01",{"date":46,"type":21},"2026-12",{"name":48,"class":49},"Axsome Therapeutics, Inc.","INDUSTRY",40]